ALK and non-small cell lung carcinoma: More recently, the anaplastic lymphoma kinase (ALK) TKI crizotinib was approved with a companion diagnostic test for the treatment of a relatively small (up to 3 to 5%) subset of patients with advanced NSCLC who harbor ALK rearrangements (9-11).